Carbohydrate Estimation Supported by the GoCARB System
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Sep 7, 2015
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
Background
For individuals with type 1 diabetes (T1D) the current gold standard to evaluate the carbohydrate (CHO) amount of a meal is by carefully weighing its different components and calculating the CHO content using reference nutritional tables. The resulting CHO amount is then used to define the insulin dose needed to avoid an abnormal postprandial glucose profile. Since this is a cumbersome procedure in real life, diabetic individuals often estimate the CHO amount based on their personal experience. Especially for food served on a plate CHO estimates are often significantly over or u...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 1 diabetes
- • Minimum age of 18 years old
- • Sensor-augmented pump therapy for at least six months
- • HbA1c levels within the last 4 months ≤ 8.5%
- • Familiar with carbohydrate (CHO) counting (e.g. CHO counting training in the past)
- • Normal insulin sensitivity (reflected by a daily insulin requirement of 0.3-1.0 U/kg body weight)
- • Able to comprehend German or English
- • Written informed consent
- • Exclusion Criteria
- • Relevant diabetic complications
- • Hypoglycemia unawareness
- • More than one episode of severe hypoglycemia as defined by American Diabetes Association in preceding 12 months
- • Pregnancy
- • Relevant psychiatric disorder
- • Active neoplasia
- • Participation in another study
- • Other individuals especially in need of protection (according to the guidelines of the Swiss Academy of Medical Sciences)
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Christoph Stettler
Principal Investigator
Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital
Stavroula Mougiakakou
Principal Investigator
Diabetes Technology Research Group, ARTORG Center for Biomedical Engineering Research, University of Bern
Markus Laimer
Principal Investigator
Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials